Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats

Hypertension

Volumn 33, Issue 2, 1999, Pages 759-765

  Matsumura, Yasuo ^a   Hashimoto, Norio ^a   Taira, Shima ^a   Kuro, Toshihiko ^a   Kitano, Rika ^a   Ohkita, Mamoru ^a   Opgenorth, Terry J ^b   Takaoka, Masanori ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Hypertension, DOCA salt; Receptors endothelin; Renal function; Vascular hypertrophy

Indexed keywords

ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; HISTOPATHOLOGY; HYPERTENSION; KIDNEY INJURY; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SODIUM BALANCE;

EID: 0033042155     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.33.2.759     Document Type: Article

References (32)

1. Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension. 1995;25:1135-1143.
2. Li JS, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension. 1994;24:183-188.
3. A-receptor antagonist FR139317 on development of hypertension and cardiovascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. Jpn J Pharmacol. 1996;70:313-319.
4. Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension. 1993;21:294-300.
5. Larivière R, Day R, Schiffrin EL. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 1993;21:916-920.
6. A receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br J Pharmacol. 1995;114:925-930.
7. Kassab S, Novak J, Miller T, Kirchner K, Granger JP. Role of endothelin in mediating the attenuated renal hemodynamics in Dahl salt-sensitive hypertension. Hypertension. 1997;30(part 2):682-686.
8. Kassab S, Miller T, Novak J, Reckelhoff J, Clower B, Granger JP. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension. 1998:31(part 2):397-402.
9. Benigni A, Zoja C, Coma D, Orisio S, Longaretti L, Bertani T, Remuzzi G. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993;44:440-444.
10. A receptor antagonist on renal function of DOCA-salt hypertensive rats. Eur J Pharmacol. 1997;319:65-69.
11. Chan L, Chittinandana A, Shapiro JI, Shanley PF, Schrier RW. Effect of an endothelin-receptor antagonist on ischemic acute renal failure. Am J Physiol. 1994;266:F135-F138.
12. A receptor antagonist in the rat. J Clin Invest. 1994;93:900-906.
13. Gellai M, Jugus M, Fletcher T, Nambi P, Ohlstein EH, Elliott JD, Brooks DP. Nonpeptide endothelin receptor antagonists, V: prevention and reversal of acute renal failure in the rat by SB209670. J Pharmacol Exp Ther. 1995;275:200-206.
14. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Macé B, Comoy E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976-1982.
15. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-tenn survival in heart failure. Nature. 1996;384:353-355.
16. A-selective receptor antagonist. J Pharmacol Exp Ther. 1996;276:473-481.
17. A-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Br J Pharmacol. 1997;121:935-940.
18. A receptor blockade attenuates the hypertension but not renal dysfunction in DOCA-salt rats. Am J Physiol. 1998;275:R245-R252.
19. Chen S-J, Chen Y-F, Opgenorth TJ, Wessale JL, Meng QC, Durand J, DiCarlo VS, Oparil S. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J Cardiovasc Pharmacol. 1997;29:713-725.
20. A receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs. J Cardiovasc Pharmacol. 1997;30:33-41.
21. B-selective, and balanced endothelin receptor antagonists. In: Abstracts of the 5th International Conference on Endothelin; September 12-15, 1997; Kyoto, Japan. Abstract O18.
22. B receptor antagonist. In: 5th International Conference on Endothelin; September 12-15, 1997; Kyoto, Japan. Abstract O21.
23. Goto K, Hama H, Kasuya Y. Molecular pharmacology and pathophysiological significance of endothelin. Jpn J Pharmacol. 1996;72:261-290.
24. Lüscher TF, Seo B-G. Bühler FR. Potential role of endothelin in hypertension: controversy on endothelin in hypertension. Hypertension. 1993; 21:752-757.
25. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83: 1774-1777.
26. ω-nitro-L-arginine methyl ester on cardiovascular structure in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens. 1996;14: 1331-1339.
27. A-receptor blocker (LU 135252) in salt-loaded uninephrectomized stroke-prone spontaneously hypertensive rats. Hypertension. 1998;31:995-1001.
28. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T, Nishikibe M, Yano M. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA. 1994;91: 4892-4896.
29. B receptor-mediated action on systemic and renal hemodynamics and urine formation in deoxycorticosterone acetate-salt-induced hypertensive rats. Biol Pharm Bull. 1998;21:800-804.
30. A receptor-mediated role of endothelin in the kidney of DOCA-salt hypertensive rats. Life Sci. 1996;58:PL1-PL7.
31. B receptor antagonist Ro 46-8443. FEBS Lett. 1996;383:42-45.
32. Firth JD, Ratcliff PJ. Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest. 1992;90:1023-1031.